Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Filings indexed 871 across all filing types
Latest filing 2022-03-14 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report". It details the reduction in shareholding by 安徽志道投资有限公司 in 圣湘生物科技股份有限公司, including specific share quantities, dates, and methods of share disposal. The document references relevant Chinese securities laws and disclosure standards specifically related to equity changes. It is a formal report of a significant shareholder's change in ownership stake, including past six months' trading activity and future plans. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document is over 5,000 characters and contains detailed substantive information about the shareholding change, not just an announcement or certification. Therefore, the correct classification is MRQ.
2022-03-14 Chinese
圣湘生物科技股份有限公司关于持股5%以上股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a change in shareholding by a shareholder holding more than 5% of the company's shares. It details the reduction in shares held by Anhui Zhidao Investment Co., Ltd., including specific dates, share quantities, and percentages before and after the change. The document explicitly states it is a "提示性公告" (a notice or alert announcement) about the change in equity holdings of a shareholder with more than 5% ownership. There is no financial data, no report attached, no management discussion, no earnings information, or other report types. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2022-03-14 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司2022年开展外汇套期保值业务的核查意见
Regulatory Filings
2022-03-14 Chinese
圣湘生物科技股份有限公司关于开展外汇套期保值业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the board of directors of 圣湘生物科技股份有限公司 regarding the approval and details of conducting foreign exchange hedging business. It includes the scope, risk analysis, risk control measures, accounting principles, and opinions from independent directors, the supervisory board, and the sponsoring institution. The document is a formal announcement of a business decision and risk management plan rather than a financial report or regulatory filing. It does not contain financial statements or quarterly/yearly results, nor is it a report publication announcement. It is a specific announcement about capital/financing-related activity (foreign exchange hedging business) and its risk management, which fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is not merely announcing a report publication; it is announcing a business activity and related approvals and risk controls.
2022-03-14 Chinese
圣湘生物科技股份有限公司关于持股5%以上股东权益变动达到1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a change in shareholding by a shareholder holding more than 5% of the company's shares. It details the reduction in shareholding percentage, the number of shares sold, and confirms that this change does not affect control of the company. The document references compliance with securities laws and disclosure requirements but does not contain financial statements or detailed financial analysis. It is a typical major shareholding notification reporting a change in significant share ownership levels crossing thresholds. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, confirming this classification with high confidence.
2022-03-11 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of obtaining a medical device registration certificate for a specific product. It includes details about the product, its intended use, registration certificate number, and the impact on the company. The document is short (1031 characters) and does not contain financial statements, audit information, or detailed financial data. It is an announcement about a regulatory approval related to product registration rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-03-08 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.